TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35802350

Group type: COMPARATOR
Intervention: Interventions to improve communication (e.g. question prompt list, with or without patient and physician training)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Interventions to improve EoL communication
Number of subjects: 8

Group type: COMPARATOR
Intervention: Family conference intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Structured serious illness conversation guide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Communication interventions (e.g. structured EoL conversations)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Communication interventions (e.g. question prompt list alone or with nurse-led communication skills training)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Interventions to improve communication
Number of subjects: 8
Study: 35802393

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of autologous adult bone marrow mononuclear cells (BMMNCs)
Number of subjects: 176
Study: 35802402

Group type: EXPERIMENTAL
Intervention: Friendship Bench (FB) program, a problem-solving therapy (PST)-based program adapted for use among people living with HIV on MMT.
Number of subjects: 0
Study: 35802405

Group type: COMPARATOR
Intervention: Insulin Glargine U300 (IGlar-300)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Insulin Degludec U100 (IDeg-100)
Number of subjects: 25
Study: 35802628

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (15 minutes)
Number of subjects: 62
Study: 35802786

Group type: EXPERIMENTAL
Intervention: GBS negative at screening
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GBS positive at screening
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: GBS colonization
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CPS-specific antibodies
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Correlation of antibody levels
Number of subjects: 70
Study: 35803260

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4
Number of subjects: 0
Study: 35803286

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (1 mg on cycle 1 day 1, 2 mg on cycle 1 day 8, 60 mg on cycle 1 day 15 and cycle 2 day 1, 30 mg on day 1 of cycle 3 and onwards)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 90
Study: 35803294

Group type: EXPERIMENTAL
Intervention: CEND-1 plus nab-paclitaxel and gemcitabine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CEND-1 monotherapy
Number of subjects: 31
Study: 35803731

Group type: EXPERIMENTAL
Intervention: Woven EndoBridge (WEB) device treatment
Number of subjects: 100
Study: 35803835

Group type: EXPERIMENTAL
Intervention: Olaparib treatment in gBRCAm cohort
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Olaparib treatment in sBRCAm cohort
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Olaparib treatment in HRD-positive cohort
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Olaparib treatment in HRD-negative cohort
Number of subjects: 272
Study: 35804188

Group type: EXPERIMENTAL
Intervention: Radium-223 therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Patients who discontinued radium-223 therapy
Number of subjects: 122
Study: 35804294

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg intravenous every 12 weeks for up to 8 doses
Number of subjects: 128
Study: 35804359

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost analysis tools for patient navigation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stakeholder engagement methods
Number of subjects: 0
Study: 35804385

Group type: EXPERIMENTAL
Intervention: Bushen Culuan Decoction 13 g three times a day for 14 days and clomiphene citrate placebo tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene citrate tablets 50 mg once a day for 5 days starting on day 5 of every menstrual period (control group).
Number of subjects: 0
Study: 35804404

Group type: EXPERIMENTAL
Intervention: Topical sirolimus solution (1 mg/mL) applied once daily for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no treatment)
Number of subjects: 0
Study: 35804409

Group type: EXPERIMENTAL
Intervention: Nasal transcriptomics (Transcriptomic Subgroup B or D)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nasal transcriptomics
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Serum biomarkers
Number of subjects: 63
Study: 35804417

Group type: EXPERIMENTAL
Intervention: Mobile mammography unit in addition to current OBCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current OBCS without mobile unit
Number of subjects: 0
Study: 35804453

Group type: EXPERIMENTAL
Intervention: Extended prone positioning (median duration 39 hours)
Number of subjects: 81
Study: 35804454

Group type: EXPERIMENTAL
Intervention: Standard treatment: rifampicin plus clarithromycin for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Investigational treatment: rifampicin plus clarithromycin plus amoxicillin/clavulanate for 4 weeks
Number of subjects: 70
Study: 35804457

Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride (NSF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 50
Study: 35805716

Group type: EXPERIMENTAL
Intervention: Acute triiodothyronine (T3) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T3 administration
Number of subjects: 0
Study: 35806269

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with adjunctive systemic antibiotics (amoxicillin/metronidazole)
Number of subjects: 209
Study: 35808889

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 98
Study: 35808998

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) combined with prolonged exposure (PE) therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study: 35809096

Group type: EXPERIMENTAL
Intervention: CIP patients
Number of subjects: 40
Study: 35809937

Group type: EXPERIMENTAL
Intervention: Maintenance Oral Corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biologics
Number of subjects: 0
Study: 35810079

Group type: EXPERIMENTAL
Intervention: Rescue subcutaneous (s.c.) progesterone therapy (25 mg)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Vaginal progesterone tablet plus i.m. progesterone (control group)
Number of subjects: 238
Study: 35810243

Group type: EXPERIMENTAL
Intervention: DMEK (Descemet membrane endothelial keratoplasty)
Number of subjects: 43
Study: 35810296

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SO) titrated to a goal serum phosphate of <5.5 mg/dL
Number of subjects: 17
Study: 35810311

Group type: EXPERIMENTAL
Intervention: Miridesap/dezamizumab
Number of subjects: 23
Study: 35810553

Group type: EXPERIMENTAL
Intervention: Nazartinib 150 mg once daily
Number of subjects: 45
Study: 35810555

Group type: EXPERIMENTAL
Intervention: Cyclic fasting-mimicking diet (FMD) combined with standard anticancer therapies
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard anticancer therapies
Number of subjects: 101
Study: 35810953

Group type: EXPERIMENTAL
Intervention: Low-profile (LP) devices
Number of subjects: 466

Group type: COMPARATOR
Intervention: Standard-profile (SP) devices
Number of subjects: 466
Study: 35811565

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culprit-vessel-only revascularization
Number of subjects: 0
Study: 35812102

Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 516

Group type: COMPARATOR
Intervention: Non-COVID controls
Number of subjects: 516
Study: 35812443

Group type: EXPERIMENTAL
Intervention: TILTregSig (prognostic signature of Tregs consisting of five mRNAs)
Number of subjects: 0
Study: 35812817

Group type: EXPERIMENTAL
Intervention: Elobixibat (EXB) 10 mg/day for 4 weeks
Number of subjects: 40
Study: 35812823

Group type: EXPERIMENTAL
Intervention: Autonomous in-vehicle technologies (Level 1) activated
Number of subjects: 105

Group type: COMPARATOR
Intervention: No autonomous in-vehicle technologies activated (control condition)
Number of subjects: 105
Study: 35813254

Group type: EXPERIMENTAL
Intervention: Transperitoneal Robotic-assisted Laparoscopic Pyeloplasty (T-RALP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Retroperitoneal Robotic-assisted Laparoscopic Pyeloplasty (R-RALP)
Number of subjects: 106
Study: 35813373

Group type: EXPERIMENTAL
Intervention: Ceftriaxone for 1 week
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ampicillin plus gentamicin (standard-of-care)
Number of subjects: 300
Study: 35813634

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (weight loss associated with lifestyle changes)
Number of subjects: 12
Study: 35814366

Group type: EXPERIMENTAL
Intervention: AHCC 3-g supplementation by mouth once daily on empty stomach for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo once daily for 12 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AHCC supplementation (unblinded) for 6 months after placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AHCC supplementation overall (blinded and unblinded)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Suppression of IFN-β to less than 20 pg/ml
Number of subjects: 50
Study: 35814730

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 2479

Group type: COMPARATOR
Intervention: Control for housing, relationship status, age, childhood abuse, and potential effect of IPV on later food insecurity
Number of subjects: 2479
Study: 35814763

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging using infrared scanning laser ophthalmoscopy (SLO) and optical coherence tomography (OCT) over a mean period of 32.8 months (range, 18-72 months) with a mean interval between imaging sessions of 2.4 months (range, 1.4-3.8 months).
Number of subjects: 6
Study: 35815043

Group type: EXPERIMENTAL
Intervention: COVID-19-related psychosocial care (COVID-psyCare) provided in hospitals
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Specific cooperation structures for COVID-psyCare
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: COVID-psyCare for patients
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: COVID-psyCare for relatives
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: COVID-psyCare for staff
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Time resources invested for patients, relatives, and staff
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Emerging needs for mutual exchange and support regarding COVID-psyCare
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Suggestions for future changes or improvements in COVID-psyCare
Number of subjects: 98
Study: 35815359

Group type: EXPERIMENTAL
Intervention: Various pharmacological treatments for COPD
Number of subjects: 20054

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 20054

Group type: EXPERIMENTAL
Intervention: Full model
Number of subjects: 20054

Group type: COMPARATOR
Intervention: Simplified model
Number of subjects: 20054
Study: 35815403

Group type: EXPERIMENTAL
Intervention: Selenium Trial participants
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Independent case-control study population from CORSA
Number of subjects: 1215
Study: 35815408

Group type: EXPERIMENTAL
Intervention: 9-ING-41, a selective GSK-3β inhibitor
Number of subjects: 1
Study: 35815468

Group type: EXPERIMENTAL
Intervention: Emtricitabine (F, FTC)-tenofovir disoproxil fumarate (TDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 35815644

Group type: EXPERIMENTAL
Intervention: BI 764532 (DLL3/CD3 bispecific T-cell engager)
Number of subjects: 0
Study: 35815666

Group type: EXPERIMENTAL
Intervention: Standardized feminizing hormone therapy (sFHT; oestradiol valerate 2-6 mg plus spironolactone 100-300 mg) plus PrEP for 12 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Any feminizing hormone therapy (aFHT) plus PrEP (long-term PK)
Number of subjects: 43

Group type: COMPARATOR
Intervention: PrEP only (noFHT)
Number of subjects: 43
Study: 35815954

Group type: EXPERIMENTAL
Intervention: Binge-eating symptoms (BE)
Number of subjects: 482

Group type: COMPARATOR
Intervention: No binge-eating symptoms (Control group)
Number of subjects: 482
Study: 35816217

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 35816241

Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IN) with immune-enhancing feed plus maltodextrin load on the day of surgery (Group A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No immunonutrition nor fast track management (Group B)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IN) with ERAS protocol (Group A)
Number of subjects: 2
Study: 35816269

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence lymphatic imaging (NIRF-LI) surveillance
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dermal backflow detected by NIRF-LI
Number of subjects: 42
Study: 35816378

Group type: EXPERIMENTAL
Intervention: Ovation Alto stent graft
Number of subjects: 300
Study: 35816381

Group type: EXPERIMENTAL
Intervention: Daily physical activity program including 3 types of exercises: staying out of bed for at least 3 hours, performing balance exercises while standing for 2 minutes, and the Five Times Sit to Stand transfer exercise.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Daily physical activity program
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Five Times Sit to Stand test
Number of subjects: 266
Study: 35816397

Group type: EXPERIMENTAL
Intervention: Remote nutritional intervention based on Mediterranean diet (MD) enriched with extra virgin olive oil (EVOO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35816411

Group type: EXPERIMENTAL
Intervention: ARCoV vaccine
Number of subjects: 0
Study: 35816490

Group type: EXPERIMENTAL
Intervention: APN01 (soluble human recombinant ACE2) administered via nebulizer, twice daily for two weeks at maximum feasible concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APN01 (soluble human recombinant ACE2)
Number of subjects: 0
Study: 35816664

Group type: EXPERIMENTAL
Intervention: Eprenetapopt plus azacitidine
Number of subjects: 33
Study: 35816681

Group type: EXPERIMENTAL
Intervention: You + ME Registry
Number of subjects: 4339
Study: 35816737

Group type: EXPERIMENTAL
Intervention: Overeating for one week in exercise trained adults (EX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overeating for one week in untrained adults (UT)
Number of subjects: 0
Study: 35816744

Group type: EXPERIMENTAL
Intervention: 6-month multicomponent exercise training (MCT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 35816831

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco®)
Number of subjects: 72
Study: 35816941

Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (age-matched, no ADHD)
Number of subjects: 27
Study: 35816942

Group type: EXPERIMENTAL
Intervention: Cyberknife System treatment plans based on unrotated volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyberknife System treatment plans based on envelope of unrotated and rotated volumes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma analysis of treatment plans
Number of subjects: 0
Study: 35816951

Group type: EXPERIMENTAL
Intervention: Retifanlimab 500 mg administered intravenously every 4 weeks
Number of subjects: 94
Study: 35817031

Group type: EXPERIMENTAL
Intervention: NT-proBNP and osteoprotegerin
Number of subjects: 4957

Group type: EXPERIMENTAL
Intervention: Trefoil factor 3
Number of subjects: 4957

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2
Number of subjects: 4957

Group type: EXPERIMENTAL
Intervention: NT-proBNP plus clinical risk factors
Number of subjects: 4957

Group type: EXPERIMENTAL
Intervention: Other biomarkers
Number of subjects: 4957
Study: 35817091

Group type: EXPERIMENTAL
Intervention: Wood or kerosene cooking fuel
Number of subjects: 798

Group type: COMPARATOR
Intervention: Age (per year increase)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Baseline myopia
Number of subjects: 798

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 798
Study: 35817480

Group type: EXPERIMENTAL
Intervention: TransCon IL-2 β/γ
Number of subjects: 2
Study: 35817563

Group type: EXPERIMENTAL
Intervention: Prophylactic total gastrectomy (PTG)
Number of subjects: 120
Study: 35818046

Group type: EXPERIMENTAL
Intervention: Resilience assessment using the 25-item Connor-Davidson resilience scale (CD-RISC)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Frail patients
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 143
Study: 35818348

Group type: EXPERIMENTAL
Intervention: Point-of-care nerve conduction study device (Mediracer® NCS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OX) treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-CIPN20 questionnaire
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NPSI questionnaire
Number of subjects: 12
Study: 35818509

Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin
Number of subjects: 0
Study: 35818548

Group type: EXPERIMENTAL
Intervention: Estimated peak oxygen consumption (Vo2) using HF-FRIEND or oncology-specific equations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Measured peak oxygen consumption (Vo2)
Number of subjects: 0
Study: 35818888

Group type: EXPERIMENTAL
Intervention: School-based stigma and disclosure strategies
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Supportive relationships
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: HIV care engagement strategies
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Support for school-going adolescents
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Medication management strategies
Number of subjects: 83
Study: 35819130

Group type: EXPERIMENTAL
Intervention: Weekly digital follow-up of lung cancer patients
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Weekly digital follow-up of lung cancer patients (pilot study)
Number of subjects: 201
Study: 35819199

Group type: EXPERIMENTAL
Intervention: PROACTIA score
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: P-wave duration, PAC/24h, NT-proBNP, LAVI
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc, P-wave duration, P-wave morphology, PAC/24h, supraventricular tachycardia/24h, left atrial end-systolic volume index (LAVI), Troponin-T, NT-proBNP, D-dimer
Number of subjects: 236

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 236
Study: 35819312

Group type: EXPERIMENTAL
Intervention: Next-generation pathology (NGP) detection of immune synapses (ai-iSYN)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: NGP-detected immune synapses
Number of subjects: 53

Group type: COMPARATOR
Intervention: iPAIRs
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: SMAC formation in iPAIR-engaged lymphocytes
Number of subjects: 53
Study: 35819325

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension (PAH) and PH secondary to lung disease
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Control group (230 patients)
Number of subjects: 1823
Study: 35819446

Group type: EXPERIMENTAL
Intervention: miR-146b-5p mimic administration to NSG mice engrafted with CLL cells
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Downregulation of miR-146b-5p with specific miRNA inhibitors in vitro
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Expression of miR-146b-5p with miRNA mimics in vitro
Number of subjects: 224

Group type: COMPARATOR
Intervention: Observation of miR-146b-5p concentrations in untreated patients
Number of subjects: 224
Study: 35819490

Group type: EXPERIMENTAL
Intervention: Percutaneous laparoscopy (PERC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional laparoscopy (LAP)
Number of subjects: 59
Study: 35819829

Group type: EXPERIMENTAL
Intervention: PRO-ECO intervention (n=4 ECECs)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Wait-list control (n=4 ECECs)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: PRO-ECO intervention
Number of subjects: 130
Study: 35820054

Group type: EXPERIMENTAL
Intervention: Opal patient portal intervention for distance monitoring of self-isolating patients with COVID-19, involving daily self-assessment of symptoms, vital signs, and mental health monitored by a nurse, with teleconsultations as needed.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Qualitative interviews conducted with stakeholders (patient participants, health care professionals, technology developers, study administrators).
Number of subjects: 50
Study: 35820082

Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Number of subjects: 0
Study: 35820227

Group type: EXPERIMENTAL
Intervention: Frequent productive cough (defined as cough and sputum production most or several days/week for the past 3 months)
Number of subjects: 7125

Group type: COMPARATOR
Intervention: Patients without frequent productive cough
Number of subjects: 7125
Study: 35820397

Group type: EXPERIMENTAL
Intervention: Poziotinib
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Poziotinib (near-loop insertions)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Poziotinib (far-loop insertions)
Number of subjects: 50
Study: 35820684

Group type: EXPERIMENTAL
Intervention: Educational brochures and short educational sessions for medical staff on safe gabapentinoid prescribing practices.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 160
Study: 35820718

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion (1×10^6 cells)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion
Number of subjects: 6
Study: 35820756

Group type: EXPERIMENTAL
Intervention: Operationalise a functional malaria molecular surveillance system in Mozambique
Number of subjects: 0
Study: 35820771

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0